The
European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT),
together with the GMDP Inspectors Working Group and the Blood Products Working
Party, have released a questions and answers (Q&A) document on how
companies should go about using OOS batches of authorized cell or tissue-based
advanced therapy medicinal products (ATMPs).
Microbiology, pharmaceuticals, healthcare and contamination control news and discussion site. Edited by Dr. Tim Sandle (established 2010)
Thursday, 15 August 2019
EMA Offers Q&A on Using OOS Batches of Authorized ATMPs
Subscribe to:
Post Comments (Atom)
No comments:
Post a comment
Pharmaceutical Microbiology Resources